FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
Tiziana Life Sciences (TLSA) has received FDA approval to expand its Intermediate-Size Patient Population Access program for its intranasal foralumab treatment in secondary progressive multiple sclerosis (SPMS). Following promising clinical responses from two patients, Tiziana aims to initiate treatment for eight additional patients. The dosing regimen will remain at 50 mcg three times a week, with the potential for dose escalation. The study is expected to begin in July 2022, focusing on safety, tolerability, and clinical benefits.
- FDA approval for expanded access to treat eight more SPMS patients.
- Positive preliminary clinical data from the first two patients indicates potential efficacy.
- Dosing regimen includes the option for dose escalation to enhance clinical benefits.
- None.
- This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.
- Tiziana recently reported clinical data from the first SPMS patient showing beneficial responses following six months of treatment with intranasal foralumab, a fully human anti-CD3 monoclonal antibody
- The clinical data update from the second SPMS patient is expected in May 2022, representing 3 months of intranasal foralumab therapy.
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced that its collaborators at the Brigham and Women’s Hospital (BWH) Boston MA have received a ‘Study May Proceed Letter’ from the U.S. Food and Drug Administration (FDA) permitting initiation of treatment in up to an additional eight SPMS patients as part of an Intermediate-Size Patient Population Expanded Access IND.
The safety, tolerability, and clinical responses from the first two SPMS patients were submitted to the FDA to seek permission to treat up to an additional eight SPMS patients with the goal of obtaining more clinical data to assess robustness of the clinical responses. As part of the original treatment plan, the foralumab dose will remain 50 mcg three times a week (MWF), which is the same dose administered previously to the first two SPMS patients. The dosing regimen in this IND also has a provision for dose escalation up to 100 mcg three times a week (MWF) as an option to improve clinical benefit, if needed.
The treatment plan will be submitted to the Institutional Review Board (IRB) of BWH prior to initiation of patient enrollment and initiation of the study, which is anticipated to be initiated in July 2022. While the primary objectives are safety, tolerability and patient benefits, additional measures will assess clinical and immune responses, including imaging by positron emission tomography (PET), specifically to assess inhibition of microglial activation.
Excessive activation of microglial cells is well-known to be associated with neurodegenerative diseases such as multiple sclerosis (MS), Alzheimer’s disease and Parkinson1. The underlying causes of these diseases lead to microglial activation and brain inflammation2. Thus, inhibition of microglial activation is an important target for drug discovery and development for neurodegenerative diseases. Several FDA-approved drugs, such as TYSABRI® , MAYZENT® and ZEPOSIA® suppress microglial activation and exert neuroprotective effects in the central nervous system (CNS) in animal studies but longitudinal assessment of drug effects on microglial activation in SPMS patients remains to be determined. On March 10, 2022, Tiziana reported clinical data from a SPMS patient treated with intranasal foralumab for six months, which showed that foralumab inhibited microglial cell activation in all areas of the brain as assessed by PET imaging3.
Howard Weiner, M.D., Director of the Multiple Sclerosis Program at the BWH and Chairman of Tiziana's Scientific Advisory Board, commented, “Treatment with intranasal foralumab is a novel physiological approach to stimulate the mucosal immune system to induce disease-modifying benefits in the CNS by dampening microglial inflammation. The first validation of our innovative approach came from our recently reported results showing positive clinical benefits and microglial modulation in a patient with secondary progressive multiple sclerosis who was treated for six months with nasal Foralumab3. This now opens the door to treat other neurologic diseases which have microglial inflammation - such as Alzheimer’s disease - with intranasal foralumab. "
Dr. Tanuja Chitnis, M.D., Professor at the BWH and a member of Tiziana's Scientific Advisory Board, commented, “Therapies to slow progression in multiple sclerosis are much needed. We are grateful to have the opportunity to offer intranasal foralumab to progressive MS patients."
Cited references
- Luo, C., et al., Neuropsychiatric Dis Treat. 2017; 13: 1661–1667.
- Alan, C-B., et al., Neuron 2018 Feb 21;97(4):742-768
- Tiziana Press Release March 10, 2022
About Foralumab
Foralumab (TZLS-401; formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells (Tregs), thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura et al., Clin. Immunol. 183:240-246, 2017). Once a day treatment for 10 consecutive days with intranasal foralumab was not only well tolerated but also produced strong clinical responses in COVID-19 patients (Moreira et al., Front Immunol 12: 709861,2021). Based on these studies, the intranasal and oral administration of foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral, and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
| Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com | |
| Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com |
FAQ
What recent FDA news involves Tiziana Life Sciences (TLSA)?
What is the purpose of the Intermediate-Size Patient Population Access program for TLSA?
When is Tiziana Life Sciences expected to start the new patient study?
What treatment is being tested in Tiziana's expanded access program?
What were the results from earlier patients treated with intranasal foralumab?
